Chris Degnan

Insider Reports History

Location
West Chester, PA
Signature
/s/ Jason D. Smith, Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Chris Degnan:

Company Role Class Num Shares Value Price $ Report Date Ownership
UroGen Pharma Ltd. Chief Financial Officer Ordinary Shares 2,280 $38,418 $16.85 08 Oct 2025 Direct
Galera Therapeutics, Inc. Chief Financial Officer Common Stock 10,000 $22,470 $2.25 13 Mar 2023 Direct
Galera Therapeutics, Inc. Chief Financial Officer Stock Option (Right to Buy) 185,000 25 Feb 2023 Direct
UroGen Pharma Ltd. Chief Financial Officer Employee Stock Option (right to buy) 74,142 08 Oct 2024 Direct
UroGen Pharma Ltd. Chief Financial Officer Restricted Stock Units 8,967 08 Oct 2025 Direct

Insider Reports Filed by Chris Degnan

Symbol Company Period Transactions Value $ Form Type Role Filing Time
URGN UroGen Pharma Ltd. 08 Oct 2025 3 -$37,121 4 Chief Financial Officer 09 Oct 2025, 13:37
URGN UroGen Pharma Ltd. 08 Oct 2024 2 $0 4 Chief Financial Officer 09 Oct 2024, 16:22
URGN UroGen Pharma Ltd. 08 Oct 2024 0 $0 3 Chief Financial Officer 09 Oct 2024, 16:21
GRTX Galera Therapeutics, Inc. 13 Mar 2023 1 +$19,593 4 Chief Financial Officer 14 Mar 2023, 08:30
GRTX Galera Therapeutics, Inc. 25 Feb 2023 1 $0 4 Chief Financial Officer 28 Feb 2023, 17:57
GRTX Galera Therapeutics, Inc. 28 Feb 2022 1 $0 4 Chief Financial Officer 02 Mar 2022, 15:05